Saratov JOURNAL of Medical and Scientific Research
Home

Inflammation and coagulation markers in patients with soft tissue bleeding and severe COVID-19

Year: 2022, volume 18 Issue: №3 Pages: 398-403
Heading: Рathophysiology Article type: Original article
Authors: Dzhurakulov Sh.R., Sazhnov D.N., Tagaev N.B., Tashliev K.V., Kiselev A.R.
Organization: National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia , Russian Research Medical University n. a. N.I. Pirogov, Saratov State Medical University, О. M. Filatov City Clinical Hospital №15 of the Moscow City Health Department
Summary:

Objective: to evaluate some inflammation and coagulation markers to be used as soft tissue bleeding predictors in patients with severe COVID-19. Material and methods. A retrospective analysis of the case histories of 24 patients with severe COVID-19 was carried out. Inflammation (procalcitonin, ferritin interleukin-6 and C-reactive protein) and coagulation (international normalized ratio, activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimer) laboratory markers were studied. Results. The baseline median of procalcitonin in the died patients was 2 times higher than in the survived patients (0.4 and 0.2 ng/mL respectively). In the group of deceased patients, there was a significant increase in the values of this indicator (from 0.4 to 1.5 ng/ml), in contrast to its decrease in the group of surviving patients (from 0.2 to 0.1 ng/ml). Similar dynamics were observed with respect to other inflammation markers: ferritin, IL-6 and CRP (survived/died subjects [baseline/last measurement]: 663/1020 vs. 550/520 mg/M; 578/393 vs. 263/1000 pg/mL; 25/14 vs. 68/82 mg/L, respectively). Conclusion. The increase in the levels of the markers of inflammation studied by us is associated with an increased risk of bleeding into soft tissues, while indicators of coagulation homeostasis cannot be reliable predictors of the occurrence of bleeding into soft tissues.

Keywords: COVID-19, inflammation and coagulation markers, soft tissue bleeding, transcatheter arterial embolization

Bibliography:
1. LippiG, Sanchis-GomarF, Favaloro EJ,etal. Coronavirus disease 2019-associated coagulopathy. Mayo Clin Proc2021; 96 (1): 203-17.
2. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (3): 872-88.
3. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state of-the-art review. J Am Coll Cardiol 2020; 75 (23): 2950-73.
4. Nagele MP, Haubner B, Tanner FC, et al. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis 2020; (314): 58-62.
5. Chan NC, Weitz Jl. COVID-19 coagulopathy, thrombosis, and bleeding. Blood 2020; 136 (4): 381-3.8 6. Klok FA, Kruip MJ, Meer NJ, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; (191): 145-7.
7. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04): 844-7.
8. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol 2020; 76 (16): 1815-26.
9. Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death with COVID-19. PLoS One 2020; 15 (7): e0235458.
10. Kumar A, Arora A, Sharma P, et al. Clinical features of COVID-19 and factors associated with severe clinical course: A systematic review and meta-analysis. SSRN 2020; 3566166.
11. Rogani S, Calsolaro V, Franchi R, et al. Spontaneous muscle hematoma in older patients with COVID-19: Two case reports and literature review. ВМС Geriatrics 2020; 20 (1): 539.
12. Reisi-Vanani V, Lorigooini Z, Dayani MA, et al. Massive intraperitoneal hemorrhage in patients with COVID-19: A case series. J Thromb Thrombolysis 2021; (52): 338-44.
13. Shah M, Colombo JP, Chandna S, Rana H. Life-threatening retroperitoneal hematoma in a patient with COVID-19. Case Rep Hematol 2021; (2021): 8774010.
14. Abate V, Casoria A, Rendina D, et al. Spontaneous muscle hematoma in patients with COVID-19: A systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; (48): 100-8.
15. Marietta M, Coluccio V, Luppi M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med 2020; 15 (08): 1375-87.
16. Riu P, Albarello F, Di Stefano F, et al. Management of spontaneous bleeding in COVID-19 inpatients: is embolization always needed? J Clin Med 2021; (10): 4119. 17. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; (395): 1417-8.
18. Kong WK, Cho KT, Lee HJ, et al. Femoral neuropathy due to iliacus muscle hematoma in a patient on warfarin therapy. J Korean Neurosurg Soc2012; (51): 51-3.
19. Hu R, Han Ch, Pei S, et al. Procalcitonin levels in COVID-19 patients. Int J Antimicrob Agents 2020; 56 (2): 106051.
20. Al-Samkari H, Gupta S, Leaf RK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med 2021; (174): 622-32.

AttachmentSize
2022_3_398-403.pdf316.86 KB
All articles of the authors: Dzhurakulov Sh.R., Kiselev A.R., Sazhnov D.N., Tagaev N.B., Tashliev K.V.

No votes yet